Related Experiment Video
Updated: Apr 23, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Immune-related gene expression profiling and alectinib efficacy for patients with ALK-Rearranged non-small cell lung
Takashi Kurosaki1, Shinichiro Suzuki1, Yasutaka Watanabe2
1Department of Medical Oncology, Kindai University Faculty of Medicine, Sakai, Japan.
Background:
The development of resistance to anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors and a poor response to immune checkpoint inhibitors (ICIs) remain challenges in ALK-rearranged non-small cell lung cancer (NSCLC). We performed immune-related gene expression profiling (irGEP) for ALK-rearranged NSCLC to assess the characteristics of the tumor microenvironment and explore potential therapeutic avenues.
Patients And Methods:
This study analyzed tumor samples from the ALCURE trial, a prospective observational study examining the efficacy of and mechanisms of resistance to alectinib in patients with ALK-rearranged NSCLC. The irGEP analysis was performed with a panel encompassing 750 immune-related genes.
Results:
Tumor samples from 52 of the 249 ALCURE trial patients were analyzed. Tumors with high CD8A expression showed upregulation of SNAI1 and downregulation of CDH1, with these genes encoding an epithelial-mesenchymal transition (EMT)-related transcription factor and E-cadherin, respectively, suggestive of EMT progression in these tumors. Tumors with high CD8A expression also manifested downregulation of genes related to tumor angiogenesis, including ANGPT2 (angiopoietin-2) and FLT1 (VEGF receptor 1), suggestive of a quiescent angiogenic state that may facilitate the recruitment of CD8+ T cells. Progression-free survival on alectinib appeared longer in patients with high than in those with low CD8A expression; however, this difference was not statistically conclusive (HR, 0.49 [95% CI, 0.18-1.35]).
Conclusions:
CD8+ T cell infiltration may be associated with the alectinib efficacy in ALK-rearranged NSCLC. Anti-angiogenic therapies may enhance antitumor immunity and thereby augment the efficacy of alectinib as well as that of ICIs for such tumors.
Insights
CD8+ T cell infiltration in ALK-rearranged NSCLC may predict alectinib response. Combining anti-angiogenic therapies with alectinib or ICIs could improve outcomes for these patients.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Resistance to anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors and poor response to immune checkpoint inhibitors (ICIs) are challenges in ALK-rearranged non-small cell lung cancer (NSCLC).
- Understanding the tumor microenvironment is crucial for developing new therapeutic strategies.
Purpose of the Study:
- To investigate immune-related gene expression profiles (irGEP) in ALK-rearranged NSCLC.
- To explore potential therapeutic avenues by assessing tumor microenvironment characteristics.
Main Methods:
- Analysis of tumor samples from 52 patients in the ALCURE trial.
- Immune-related gene expression profiling using a panel of 750 immune-related genes.
Main Results:
- High CD8A expression correlated with epithelial-mesenchymal transition (EMT) markers (SNAI1 upregulation, CDH1 downregulation).
- High CD8A tumors showed reduced expression of angiogenesis-related genes (ANGPT2, FLT1), suggesting a quiescent angiogenic state.
- A trend towards longer progression-free survival on alectinib was observed in patients with high CD8A expression, though not statistically significant.
Conclusions:
- CD8+ T cell infiltration is potentially associated with alectinib efficacy in ALK-rearranged NSCLC.
- Anti-angiogenic therapies may enhance antitumor immunity, improving the efficacy of alectinib and ICIs in these tumors.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
04:36Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
